조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 조사년월 : 2023년07월
세포 분석 (Cell Analysis) 시장 : 제품 및 서비스 (소모품, 장비), 기술 (유동 세포 계측, PCR, 현미경), 프로세스 (계수, 생존, 증식, 상호 작용, 단일 세포 분석), 최종 사용자 (제약, 생명 공학) – 2028 까지의 세계 예측
Cell Analysis Market by Product & Service (Consumables, Instruments), Technique (Flow Cytometry, PCR, Microscopy), Process (Counting, Viability, Proliferation, Interaction, Single-cell Analysis), End User (Pharma, Biotech) – Global Forecast to 2028
| 페이지수 | 242 |
| 도표수 | 272 |
| 구성 | 영문조사보고서 |
| 가격 |
The global cell analysis market is projected to reach USD 33.9 Billion by 2028 from USD 20.2 Billion in 2023, at a CAGR of 10.9% during the forecast period. Increasing adoption of novel cellular assays in various cancer research applications is one of the key opportunities in the cell analysis market. On the other hand, expensive nature of cell analysis instruments coupled with limitations on usage of certain reagents for experiments is expected to restrain the market growth.
“The reagents & consumables segment dominates the cell analysis market through the study period of 2021-2028.”
Based on product & service, the global cell analysis market is segmented into reagents & consumables, instruments, accessories, software, and services. The reagents & consumables segment represented largest market share for the year 2022, in cell analysis market. Availability of affordable consumables and reagent solutions is expected to drive the cell-based research activtites, further strengthening the market growth. Use of unique reagents & consumables in flow cytometry-based cell analysis is expected to further propel the segment growth.
“The high content screening (HCS) segment is set to register the highest growth in the cell analysis market from 2023-2028.”
Based on technique, the global cell analysis market is segmented into flow cytometry, PCR, cell microarrays, microscopy, spectrophotometry, high-content screening (HCS), and other techniques. HCS The high content screening technique is a combination of analytical approaches and high-throughput automated imaging that aids in extraction of single-cell data which is multi-parametric in nature. Moreover, expanding applications of HCS in drug discovery applications are expected to contribute to the robust growth of this segment.
“North America generated highest revenue in cell analysis market in 2022.”
Geographically, the cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2022, North America accounted for the largest share of the cell analysis market. US being the key revenue contributor to this region, exhibits a strong network of prominent industry players leading to market maturity in this region. Further, active role of the government to encourage academic & research activities create lucrative opportunities in this region, intensifying competition in the North America cell analysis market.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 37%, Tier 2: 23%, and Tier 3: 40%
• By Designation – C-level: 32%, D-level: 26%, and Others: 42%
• By Region – North America: 35%, Europe: 25%, Asia Pacific: 20%, Latin America: 12%, and the Middle East and Africa: 8%
List of Companies Profiled in the Report
• Danaher (US)
• Thermo Fisher Scientific (US)
• Becton Dickinson and Company (US)
• General Electric (US)
• Merck KGaA (US)
• Agilent Technologies (US)
• Olympus Corporation (Japan)
• Miltenyi Biotec (US)
• Bio-Rad Laboratories (US)
• BioStatus Limited (UK)
• Fluidigm Corporation (US)
• NanoCellect Biomedical (US)
• Cell Biolabs (US)
• Creative Bioarray (US)
• Meiji Techno (US)
• Promega Corporation (US)
• PerkinElmer (US)
• Tecan Trading AG (Switzerland)
• CELLINK (US)
• QIAGEN (Germany)
• Corning Incorporated (US)
• 10x Genomics (US)
• Illumina (US)
Research Coverage:
This report provides a detailed picture of the global cell analysis market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technique, process, end user, and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell analysis market. The report forecasts the revenue of the market segments with respect to four major regions.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on cell analysis offered by the top 25 players in the cell analysis market. The report analyses the cell analysis market by product & service, technique, process, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various cell analysis across key geographic regions.
• Analysis of key drivers (rising preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growing number of drug discovery activities), restraints (high cost of instruments and restrictions on reagent use), and opportunities (high growth potential of single-cell sequencing, growing applications of cell-based assays in chronic diseases and personalized medicine).
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell analysis market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the cell analysis market.
목차
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 STUDY SCOPE 33
1.3.1 SEGMENTS COVERED 33
1.3.2 YEARS CONSIDERED 34
1.4 CURRENCY 34
1.5 LIMITATIONS 34
1.6 STAKEHOLDERS 35
1.7 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.2 PRIMARY DATA 38
FIGURE 2 CELL ANALYSIS MARKET: BREAKDOWN OF PRIMARIES 38
2.2 MARKET SIZE ESTIMATION 39
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE) 39
FIGURE 4 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE SHARE ANALYSIS, 2022 39
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION (2022) 40
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 41
FIGURE 6 CELL ANALYSIS MARKET: CAGR PROJECTIONS (2023–2028) 42
FIGURE 7 CELL ANALYSIS MARKET: ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 42
2.4 DATA TRIANGULATION 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 44
2.5 INSIGHTS FROM PRIMARIES 45
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 45
2.6 RESEARCH ASSUMPTIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 46
FIGURE 11 CELL ANALYSIS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 12 CELL ANALYSIS MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 48
FIGURE 13 CELL ANALYSIS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 49
FIGURE 14 CELL ANALYSIS MARKET: GEOGRAPHICAL SNAPSHOT 50
4 PREMIUM INSIGHTS 51
4.1 CELL ANALYSIS MARKET OVERVIEW 51
FIGURE 15 INCREASING FUNDING FOR CELL-BASED RESEARCH TO DRIVE MARKET 51
4.2 NORTH AMERICA: CELL ANALYSIS MARKET SHARE, BY PRODUCT & SERVICE (2022) 52
FIGURE 16 REAGENTS & CONSUMABLES SEGMENT HELD LARGEST MARKET SHARE IN 2022 52
4.3 NORTH AMERICA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 53
FIGURE 17 FLOW CYTOMETRY SEGMENT TO DOMINATE NORTH AMERICAN MARKET IN 2028 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 55
FIGURE 18 CELL ANALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
TABLE 1 CELL ANALYSIS MARKET: IMPACT ANALYSIS 55
5.2.1 DRIVERS 56
5.2.1.1 Growing preference for cell-based assays in drug discovery 56
5.2.1.2 Increasing funding for cell-based research 56
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2021 (USD MILLION) 57
5.2.1.3 Rising number of drug discovery activities 57
5.2.2 RESTRAINTS 58
5.2.2.1 High cost of instruments and restrictions on reagent use 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 High growth potential of single-cell sequencing 58
5.2.3.2 Application scope of novel cell-based assays in cancer research 58
5.2.4 CHALLENGES 60
5.2.4.1 Standardization of protocols and data integration & quality control for developing cell therapies 60
5.3 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 3 CELL ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.3.1 THREAT OF NEW ENTRANTS 60
5.3.2 THREAT OF SUBSTITUTES 61
5.3.3 BARGAINING POWER OF BUYERS 61
5.3.4 BARGAINING POWER OF SUPPLIERS 61
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.4 VALUE CHAIN ANALYSIS 62
FIGURE 19 CELL ANALYSIS MARKET: VALUE CHAIN ANALYSIS 62
5.5 ECOSYSTEM ANALYSIS 63
FIGURE 20 CELL ANALYSIS MARKET: ECOSYSTEM ANALYSIS 64
5.6 REGULATORY ANALYSIS (FLOW CYTOMETRY-BASED CELL ANALYSIS) 64
5.6.1 STRINGENT FDA REQUIREMENTS 64
5.6.2 STRINGENT ANALYTE-SPECIFIC REAGENT RULE 64
5.6.3 LACK OF WELL-DEFINED VALIDATION PROTOCOLS FOR CELL-BASED ASSAYS 65
5.6.4 ABSENCE OF ESTABLISHED LABORATORY-DEVELOPED TEST GUIDELINES ON CELL-BASED FLUORESCENCE ASSAYS 65
5.6.5 GREATER GLOBAL RECOGNITION FOR IVD CE MARK APPROVALS 65
5.6.6 US REIMBURSEMENT SCENARIO 65
5.7 TECHNOLOGY ANALYSIS 66
FIGURE 21 TECHNOLOGY ANALYSIS: CELL ANALYSIS MARKET 66
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 67
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
FIGURE 22 CELL ANALYSIS MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 67
5.9.2 CELL ANALYSIS MARKET: BUYING CRITERIA 68
FIGURE 23 KEY BUYING CRITERIA OF CELL ANALYSIS PRODUCTS 68
5.10 KEY CONFERENCES AND EVENTS, 2023–2024 68
TABLE 4 CELL ANALYSIS CONFERENCES (2023–2024) 68
5.11 PRICING ANALYSIS 69
5.11.1 AVERAGE SELLING PRICES OF CELL ANALYSIS PRODUCTS & SERVICES 69
TABLE 5 AVERAGE SELLING PRICES OF CELL ANALYSIS PRODUCTS & SERVICES (TOP 5 KEY PLAYERS)* 69
5.11.2 AVERAGE SELLING PRICE TREND 70
6 CELL ANALYSIS MARKET, BY PRODUCT & SERVICE 71
6.1 INTRODUCTION 72
TABLE 6 CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 72
6.2 REAGENTS & CONSUMABLES 72
6.2.1 DEVELOPMENT OF NOVEL CELL ANALYSIS KITS & REAGENTS FOR FLOW CYTOMETRY TO BOOST GROWTH 72
TABLE 7 REAGENTS & CONSUMABLES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 73
TABLE 8 NORTH AMERICA: CELL ANALYSIS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 9 EUROPE: CELL ANALYSIS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION) 74
TABLE 10 ASIA PACIFIC: CELL ANALYSIS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION) 74
6.3 INSTRUMENTS 75
6.3.1 INNOVATIONS IN CELL ANALYSIS INSTRUMENTS FOR DRUG DISCOVERY TO DRIVE MARKET 75
TABLE 11 INSTRUMENTS: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 76
TABLE 12 NORTH AMERICA: CELL ANALYSIS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 13 EUROPE: CELL ANALYSIS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 14 ASIA PACIFIC: CELL ANALYSIS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 77
6.4 ACCESSORIES 78
6.4.1 USE OF ACCESSORIES TO CUSTOMIZE FLOW CYTOMETRY INSTRUMENTS TO BOOST SEGMENT GROWTH 78
TABLE 15 ACCESSORIES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 78
TABLE 16 NORTH AMERICA: CELL ANALYSIS MARKET FOR ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 17 EUROPE: CELL ANALYSIS MARKET FOR ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 18 ASIA PACIFIC: CELL ANALYSIS MARKET FOR ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.5 SOFTWARE 80
6.5.1 EXPANDING POOL OF KEY PLAYERS INTRODUCING UNIQUE DATA INTERPRETATION SOFTWARE TO DRIVE SEGMENT 80
TABLE 19 SOFTWARE: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 20 NORTH AMERICA: CELL ANALYSIS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 21 EUROPE: CELL ANALYSIS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 22 ASIA PACIFIC: CELL ANALYSIS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 83
6.6 SERVICES 83
6.6.1 WORKFLOW CONTINUITY AND HIGH-PERFORMANCE ATTRIBUTES TO BOOST DEMAND FOR REMOTE SERVICES 83
TABLE 23 SERVICES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 24 NORTH AMERICA: CELL ANALYSIS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 25 EUROPE: CELL ANALYSIS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 26 ASIA PACIFIC: CELL ANALYSIS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 85
7 CELL ANALYSIS MARKET, BY TECHNIQUE 86
7.1 INTRODUCTION 87
TABLE 27 CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 87
7.2 FLOW CYTOMETRY 87
7.2.1 ABILITY TO PERFORM MULTIPLE MEASUREMENTS ON SINGLE CELLS TO DRIVE SEGMENT 87
TABLE 28 FLOW CYTOMETRY: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 29 NORTH AMERICA: CELL ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 30 EUROPE: CELL ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 31 ASIA PACIFIC: CELL ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.3 PCR 90
7.3.1 EFFECTIVE MEASUREMENT AND RARE SEQUENCE MONITORING BENEFITS TO DRIVE DIGITAL PCR DEMAND 90
TABLE 32 PCR: CELL ANALYSIS MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 33 NORTH AMERICA: CELL ANALYSIS MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 34 EUROPE: CELL ANALYSIS MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 35 ASIA PACIFIC: CELL ANALYSIS MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION) 92
7.4 CELL MICROARRAYS 93
7.4.1 HIGH EXPERIMENTAL THROUGHPUT OF CELL MICROARRAYS OVER TRADITIONAL METHODS TO DRIVE SEGMENT 93
TABLE 36 CELL MICROARRAYS: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 37 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 38 EUROPE: CELL ANALYSIS MARKET FOR CELL MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 39 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION) 95
7.5 MICROSCOPY 95
7.5.1 RISING INCIDENCE OF CANCER AND GROWING INVESTMENTS IN CELL BIOLOGY TO DRIVE SEGMENT 95
TABLE 40 MICROSCOPY: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 41 NORTH AMERICA: CELL ANALYSIS MARKET FOR MICROSCOPY, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 42 EUROPE: CELL ANALYSIS MARKET FOR MICROSCOPY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 43 ASIA PACIFIC: CELL ANALYSIS MARKET FOR MICROSCOPY, BY COUNTRY, 2021–2028 (USD MILLION) 97
7.6 SPECTROPHOTOMETRY 98
7.6.1 HIGH DEMAND FOR SPECTROPHOTOMETERS IN RESEARCH SETTINGS TO SUPPORT MARKET GROWTH 98
TABLE 44 SPECTROPHOTOMETRY: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 45 NORTH AMERICA: CELL ANALYSIS MARKET FOR SPECTROPHOTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 46 EUROPE: CELL ANALYSIS MARKET FOR SPECTROPHOTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 47 ASIA PACIFIC: CELL ANALYSIS MARKET FOR SPECTROPHOTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 100
7.7 HIGH-CONTENT SCREENING 100
7.7.1 HIGH DEMAND FOR HCS IN DRUG DISCOVERY TO SUPPORT SEGMENT GROWTH 100
TABLE 48 HIGH-CONTENT SCREENING: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 49 NORTH AMERICA: CELL ANALYSIS MARKET FOR HIGH-CONTENT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 50 EUROPE: CELL ANALYSIS MARKET FOR HIGH-CONTENT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 51 ASIA PACIFIC: CELL ANALYSIS MARKET FOR HIGH-CONTENT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.8 OTHER TECHNIQUES 103
TABLE 52 OTHER TECHNIQUES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 53 NORTH AMERICA: CELL ANALYSIS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 54 EUROPE: CELL ANALYSIS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 55 ASIA PACIFIC: CELL ANALYSIS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 105
8 CELL ANALYSIS MARKET, BY PROCESS 106
8.1 INTRODUCTION 107
TABLE 56 CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 107
8.2 CELL IDENTIFICATION 108
8.2.1 INCREASING RESEARCH ACTIVITIES TO PROPEL SEGMENT GROWTH 108
TABLE 57 CELL IDENTIFICATION: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 58 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 59 EUROPE: CELL ANALYSIS MARKET FOR CELL IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 60 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 110
8.3 CELL VIABILITY 110
8.3.1 USE OF CELL VIABILITY PROCESS TO CORRELATE CELL BEHAVIOR TO CELL NUMBERS 110
TABLE 61 CELL VIABILITY: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 62 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL VIABILITY, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 63 EUROPE: CELL ANALYSIS MARKET FOR CELL VIABILITY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 64 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL VIABILITY, BY COUNTRY, 2021–2028 (USD MILLION) 112
8.4 CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION 113
8.4.1 HIGH DEMAND FOR TOXICITY TESTING IN DRUG DEVELOPMENT TO DRIVE MARKET 113
TABLE 65 CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 66 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 67 EUROPE: CELL ANALYSIS MARKET FOR CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 68 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 115
8.5 CELL PROLIFERATION 115
8.5.1 MEASUREMENT OF CELL PROLIFERATION BASED ON AVERAGE DNA CONTENT TO DRIVE SEGMENT 115
TABLE 69 CELL PROLIFERATION: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 70 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL PROLIFERATION, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 71 EUROPE: CELL ANALYSIS MARKET FOR CELL PROLIFERATION, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 72 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL PROLIFERATION, BY COUNTRY, 2021–2028 (USD MILLION) 117
8.6 CELL COUNTING AND QUALITY CONTROL 118
8.6.1 USE OF FLOW CYTOMETRY IN CELL COUNTING TO ENABLE EASY CELL DIFFERENTIATION VIA SCATTERING OR STAINING 118
TABLE 73 CELL COUNTING AND QUALITY CONTROL: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 74 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL COUNTING AND QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 75 EUROPE: CELL ANALYSIS MARKET FOR CELL COUNTING AND QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 76 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL COUNTING AND QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 120
8.7 CELL INTERACTION 120
8.7.1 ADVANCEMENT IN CELL-CELL INTERACTIONS/COMMUNICATIONS TO BOOST MARKET GROWTH 120
TABLE 77 CELL INTERACTION: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 78 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL INTERACTION, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 79 EUROPE: CELL ANALYSIS MARKET FOR CELL INTERACTION, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 80 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL INTERACTION, BY COUNTRY, 2021–2028 (USD MILLION) 122
8.8 CELL STRUCTURE STUDY 123
8.8.1 ADVANCEMENTS IN CELLULAR IMAGING TO SUPPORT MARKET GROWTH 123
TABLE 81 CELL STRUCTURE STUDY: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 82 NORTH AMERICA: CELL ANALYSIS MARKET FOR CELL STRUCTURE STUDY, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 83 EUROPE: CELL ANALYSIS MARKET FOR CELL STRUCTURE STUDY, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 84 ASIA PACIFIC: CELL ANALYSIS MARKET FOR CELL STRUCTURE STUDY, BY COUNTRY, 2021–2028 (USD MILLION) 125
8.9 TARGET IDENTIFICATION AND VALIDATION 125
8.9.1 ADOPTION OF HIGH-CONTENT SCREENING IN TARGET IDENTIFICATION TO DRIVE MARKET 125
TABLE 85 TARGET IDENTIFICATION AND VALIDATION: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 86 NORTH AMERICA: CELL ANALYSIS MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 87 EUROPE: CELL ANALYSIS MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 88 ASIA PACIFIC: CELL ANALYSIS MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 127
8.10 SINGLE-CELL ANALYSIS 128
8.10.1 EXPANDING APPLICATIONS OF SINGLE-CELL ANALYSIS IN CLINICAL RESEARCH TO PROPEL SEGMENT GROWTH 128
TABLE 89 SINGLE-CELL ANALYSIS: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 90 NORTH AMERICA: CELL ANALYSIS MARKET FOR SINGLE-CELL ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 91 EUROPE: CELL ANALYSIS MARKET FOR SINGLE-CELL ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 92 ASIA PACIFIC: CELL ANALYSIS MARKET FOR SINGLE-CELL ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION) 130
9 CELL ANALYSIS MARKET, BY END USER 131
9.1 INTRODUCTION 132
TABLE 93 CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 132
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 132
9.2.1 HIGH DEMAND FOR CELL-BASED RESEARCH IN DRUG DISCOVERY & DEVELOPMENT TO DRIVE SEGMENT 132
TABLE 94 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 95 NORTH AMERICA: CELL ANALYSIS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 96 EUROPE: CELL ANALYSIS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 97 ASIA PACIFIC: CELL ANALYSIS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 134
9.3 HOSPITALS AND CLINICAL TESTING LABORATORIES 135
9.3.1 ADOPTION OF ADVANCED TECHNOLOGIES TO SUPPORT MARKET GROWTH 135
TABLE 98 HOSPITALS AND CLINICAL TESTING LABORATORIES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 99 NORTH AMERICA: CELL ANALYSIS MARKET FOR HOSPITALS AND CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 100 EUROPE: CELL ANALYSIS MARKET FOR HOSPITALS AND CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 101 ASIA PACIFIC: CELL ANALYSIS MARKET FOR HOSPITALS AND CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 137
9.4 ACADEMIC AND RESEARCH INSTITUTES 137
9.4.1 GROWING NUMBER OF RESEARCH PROJECTS THROUGH INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET 137
TABLE 102 ACADEMIC AND RESEARCH INSTITUTES: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 103 NORTH AMERICA: CELL ANALYSIS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 104 EUROPE: CELL ANALYSIS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 105 ASIA PACIFIC: CELL ANALYSIS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 139
9.5 OTHER END USERS 140
TABLE 106 OTHER END USERS: CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 107 NORTH AMERICA: CELL ANALYSIS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 108 EUROPE: CELL ANALYSIS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 109 ASIA PACIFIC: CELL ANALYSIS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 142
10 CELL ANALYSIS MARKET, BY REGION 143
10.1 INTRODUCTION 144
TABLE 110 CELL ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 144
10.2 NORTH AMERICA 144
FIGURE 24 NORTH AMERICA: CELL ANALYSIS MARKET SNAPSHOT 145
TABLE 111 NORTH AMERICA: CELL ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 112 NORTH AMERICA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 146
TABLE 113 NORTH AMERICA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 147
TABLE 114 NORTH AMERICA: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 147
TABLE 115 NORTH AMERICA: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 148
10.2.1 US 148
10.2.1.1 Rising prevalence of cancer to drive cell analysis demand in US 148
TABLE 116 US: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149
TABLE 117 US: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 149
TABLE 118 US: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 150
TABLE 119 US: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 150
10.2.2 CANADA 151
10.2.2.1 Increasing government initiatives targeted toward stem cell research to drive market 151
TABLE 120 CANADA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 151
TABLE 121 CANADA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 152
TABLE 122 CANADA: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 152
TABLE 123 CANADA: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 153
10.3 EUROPE 153
TABLE 124 EUROPE: CELL ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 125 EUROPE: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154
TABLE 126 EUROPE: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 155
TABLE 127 EUROPE: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 156
TABLE 128 EUROPE: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.3.1 GERMANY 157
10.3.1.1 Strong R&D infrastructure, training, and awareness programs to drive market in Germany 157
TABLE 129 GERMANY: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 157
TABLE 130 GERMANY: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 158
TABLE 131 GERMANY: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 158
TABLE 132 GERMANY: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 159
10.3.2 FRANCE 159
10.3.2.1 Presence of large biotechnology industry to boost market growth 159
TABLE 133 FRANCE: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 160
TABLE 134 FRANCE: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 160
TABLE 135 FRANCE: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 161
TABLE 136 FRANCE: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 161
10.3.3 UK 162
10.3.3.1 Growing acceptance of flow cytometry products for clinical diagnostics to drive market 162
TABLE 137 UK: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162
TABLE 138 UK: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 163
TABLE 139 UK: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 163
TABLE 140 UK: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 164
10.3.4 ITALY 164
10.3.4.1 Increasing research activities and conferences to support market growth 164
TABLE 141 ITALY: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165
TABLE 142 ITALY: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 165
TABLE 143 ITALY: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 166
TABLE 144 ITALY: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
10.3.5 SPAIN 167
10.3.5.1 Strong focus on cancer diagnosis to boost flow cytometry product usage in Spain 167
TABLE 145 SPAIN: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 167
TABLE 146 SPAIN: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 168
TABLE 147 SPAIN: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 168
TABLE 148 SPAIN: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 169
10.3.6 REST OF EUROPE 169
TABLE 149 REST OF EUROPE: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 170
TABLE 150 REST OF EUROPE: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 170
TABLE 151 REST OF EUROPE: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 171
TABLE 152 REST OF EUROPE: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 171
10.4 ASIA PACIFIC 172
FIGURE 25 ASIA PACIFIC: CELL ANALYSIS MARKET SNAPSHOT 173
TABLE 153 ASIA PACIFIC: CELL ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 154 ASIA PACIFIC: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174
TABLE 155 ASIA PACIFIC: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 175
TABLE 156 ASIA PACIFIC: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 175
TABLE 157 ASIA PACIFIC: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 176
10.4.1 JAPAN 176
10.4.1.1 Easy access to technologically advanced cell analysis products to favor market growth 176
TABLE 158 JAPAN: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
TABLE 159 JAPAN: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 177
TABLE 160 JAPAN: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 178
TABLE 161 JAPAN: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 178
10.4.2 CHINA 179
10.4.2.1 Strategic partnerships in cell therapy sector to support market growth 179
TABLE 162 CHINA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 179
TABLE 163 CHINA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 180
TABLE 164 CHINA: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 180
TABLE 165 CHINA: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 181
10.4.3 INDIA 181
10.4.3.1 Government initiatives to drive market in India 181
TABLE 166 INDIA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 182
TABLE 167 INDIA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 182
TABLE 168 INDIA: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 183
TABLE 169 INDIA: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 183
10.4.4 REST OF ASIA PACIFIC 184
TABLE 170 REST OF ASIA PACIFIC: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 184
TABLE 171 REST OF ASIA PACIFIC: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 185
TABLE 172 REST OF ASIA PACIFIC: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 173 REST OF ASIA PACIFIC: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 186
10.5 LATIN AMERICA 186
10.5.1 GROWING PARTICIPATION OF ACADEMIC INSTITUTES IN RESEARCH TO ACCELERATE MARKET GROWTH 186
TABLE 174 LATIN AMERICA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 187
TABLE 175 LATIN AMERICA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 187
TABLE 176 LATIN AMERICA: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 188
TABLE 177 LATIN AMERICA: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 188
10.6 MIDDLE EAST & AFRICA 189
10.6.1 GROWING RESEARCH ACTIVITIES TO FUEL DEMAND FOR CELL ANALYSIS PRODUCTS 189
TABLE 178 MIDDLE EAST & AFRICA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 189
TABLE 179 MIDDLE EAST & AFRICA: CELL ANALYSIS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 190
TABLE 180 MIDDLE EAST & AFRICA: CELL ANALYSIS MARKET, BY PROCESS, 2021–2028 (USD MILLION) 190
TABLE 181 MIDDLE EAST & AFRICA: CELL ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
11 COMPETITIVE LANDSCAPE 192
11.1 INTRODUCTION 192
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 193
FIGURE 26 CELL ANALYSIS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 193
11.3 MARKET SHARE ANALYSIS 194
FIGURE 27 CELL ANALYSIS MARKET SHARE ANALYSIS (2022) 194
11.4 REVENUE SHARE ANALYSIS (TOP 7 MARKET PLAYERS) 195
FIGURE 28 REVENUE ANALYSIS FOR KEY COMPANIES, 2021–2022 196
11.5 COMPANY EVALUATION QUADRANT 196
11.5.1 STARS 196
11.5.2 EMERGING LEADERS 197
11.5.3 PERVASIVE PLAYERS 197
11.5.4 PARTICIPANTS 197
FIGURE 29 CELL ANALYSIS MARKET: COMPANY EVALUATION MATRIX, 2022 198
11.6 COMPETITIVE LEADERSHIP MAPPING FOR EMERGING COMPANIES/SMES/START-UPS (2022) 199
11.6.1 PROGRESSIVE COMPANIES 199
11.6.2 STARTING BLOCKS 199
11.6.3 RESPONSIVE COMPANIES 199
11.6.4 DYNAMIC COMPANIES 199
FIGURE 30 CELL ANALYSIS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS, 2022 200
11.7 COMPETITIVE SCENARIO AND TRENDS 201
11.7.1 PRODUCT LAUNCHES 201
TABLE 182 CELL ANALYSIS MARKET: PRODUCT LAUNCHES 201
11.7.2 DEALS 202
TABLE 183 CELL ANALYSIS MARKET: DEALS 202
12 COMPANY PROFILES 203
12.1 KEY COMPANIES 203
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 THERMO FISHER SCIENTIFIC INC. 203
TABLE 184 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 203
FIGURE 31 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 204
TABLE 185 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS 204
TABLE 186 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES 205
TABLE 187 THERMO FISHER SCIENTIFIC INC.: DEALS 205
12.1.2 DANAHER 207
TABLE 188 DANAHER: COMPANY OVERVIEW 207
FIGURE 32 DANAHER: COMPANY SNAPSHOT (2022) 208
TABLE 189 DANAHER: PRODUCT OFFERINGS 208
TABLE 190 DANAHER: DEALS 209
TABLE 191 DANAHER: OTHER DEVELOPMENTS 210
12.1.3 BECTON, DICKINSON AND COMPANY (BD) 211
TABLE 192 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 211
FIGURE 33 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2022) 212
TABLE 193 BECTON, DICKINSON AND COMPANY (BD): PRODUCT OFFERINGS 212
TABLE 194 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES 214
12.1.4 GENERAL ELECTRIC 215
TABLE 195 GENERAL ELECTRIC: COMPANY OVERVIEW 215
FIGURE 34 GENERAL ELECTRIC: COMPANY SNAPSHOT (2022) 216
TABLE 196 GENERAL ELECTRIC: PRODUCT OFFERINGS 216
12.1.5 MERCK KGAA 218
TABLE 197 MERCK KGAA: BUSINESS OVERVIEW 218
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2022) 219
TABLE 198 MERCK KGAA: PRODUCT OFFERINGS 219
12.1.6 AGILENT TECHNOLOGIES, INC. 221
TABLE 199 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 221
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 222
TABLE 200 AGILENT TECHNOLOGIES, INC.: PRODUCT OFFERINGS 222
TABLE 201 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES 223
12.1.7 BIO-RAD LABORATORIES, INC. 224
TABLE 202 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 224
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 225
TABLE 203 BIO-RAD LABORATORIES, INC.: PRODUCT OFFERINGS 225
TABLE 204 BIO-RAD LABORATORIES, INC.: DEALS 226
12.1.8 STANDARD BIOTOOLS 227
TABLE 205 STANDARD BIOTOOLS: COMPANY OVERVIEW 227
FIGURE 38 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2022) 227
TABLE 206 STANDARD BIOTOOLS: PRODUCT OFFERINGS 228
12.1.9 MILTENYI BIOTEC 229
TABLE 207 MILTENYI BIOTEC: COMPANY OVERVIEW 229
TABLE 208 MILTENYI BIOTEC: PRODUCT OFFERINGS 229
TABLE 209 MILTENYI BIOTEC: PRODUCT LAUNCHES 230
12.1.10 OLYMPUS CORPORATION 231
TABLE 210 OLYMPUS CORPORATION: BUSINESS OVERVIEW 231
FIGURE 39 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2022) 231
TABLE 211 OLYMPUS CORPORATION: PRODUCT OFFERINGS 232
12.1.11 BIOSTATUS LIMITED 233
TABLE 212 BIOSTATUS LIMITED: COMPANY OVERVIEW 233
TABLE 213 BIOSTATUS LIMITED: PRODUCT OFFERINGS 233
12.1.12 NANOCELLECT BIOMEDICAL 234
TABLE 214 NANOCELLECT BIOMEDICAL: BUSINESS OVERVIEW 234
TABLE 215 NANOCELLECT BIOMEDICAL: PRODUCT OFFERINGS 234
TABLE 216 NANOCELLECT BIOMEDICAL: DEALS 235
TABLE 217 NANOCELLECT BIOMEDICAL: PRODUCT LAUNCHES 235
12.1.13 CELL BIOLABS, INC. 236
TABLE 218 CELL BIOLABS, INC.: COMPANY OVERVIEW 236
TABLE 219 CELL BIOLABS, INC.: PRODUCT OFFERINGS 236
12.1.14 CREATIVE BIOARRAY 238
TABLE 220 CREATIVE BIOARRAY: COMPANY OVERVIEW 238
TABLE 221 CREATIVE BIOARRAY: SERVICE OFFERINGS 238
12.1.15 MEIJI TECHNO 239
TABLE 222 MEIJI TECHNO: COMPANY OVERVIEW 239
TABLE 223 MEIJI TECHNO: PRODUCT OFFERINGS 239
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 240
12.2.1 PROMEGA CORPORATION 240
TABLE 224 PROMEGA CORPORATION: COMPANY OVERVIEW 240
12.2.2 PERKINELMER U.S. LLC 240
TABLE 225 PERKINELMER: COMPANY OVERVIEW 240
12.2.3 TECAN TRADING AG 241
TABLE 226 TECAN TRADING AG: COMPANY OVERVIEW 241
12.2.4 CARL ZEISS AG 241
TABLE 227 CARL ZEISS AG: COMPANY OVERVIEW 241
12.2.5 SYSMEX 242
TABLE 228 SYSMEX: COMPANY OVERVIEW 242
12.2.6 CELLINK 242
TABLE 229 CELLINK: COMPANY OVERVIEW 242
12.2.7 QIAGEN 242
TABLE 230 QIAGEN: COMPANY OVERVIEW 242
12.2.8 ILLUMINA, INC. 243
TABLE 231 ILLUMINA, INC.: COMPANY OVERVIEW 243
12.2.9 CORNING INCORPORATED 243
TABLE 232 CORNING INCORPORATED: COMPANY OVERVIEW 243
12.2.10 10X GENOMICS 243
TABLE 233 10X GENOMICS: COMPANY OVERVIEW 243
13 APPENDIX 244
13.1 DISCUSSION GUIDE 244
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 247
13.3 AVAILABLE CUSTOMIZATIONS 249
13.4 RELATED REPORTS 249
13.5 AUTHOR DETAILS 250
